
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Health Policy Questions That Matter to Primary Care Practitioners: Insights From an ExpertFeaturing David B. Nash, MD, MBA, the Dr Raymond C. and Doris N. Grandon Professor of Health Policy and founding dean of the Jefferson School of Population Health at Thomas Jefferson University.






